iRegene Therapeutics Co., Ltd.

6 clinical trials · Sponsor

Record	Firm	Date
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery (NCT07550374)	iRegene Therapeutics Co., Ltd.	2026-05-01
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. (NCT07102342)	iRegene Therapeutics Co., Ltd.	2026-01-12
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy (NCT07289477)	iRegene Therapeutics Co., Ltd.	2026-01-05
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease (NCT07028632)	iRegene Therapeutics Co., Ltd.	2025-06-30
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease (NCT06608355)	iRegene Therapeutics Co., Ltd.	2024-08-23
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease (NCT06167681)	iRegene Therapeutics Co., Ltd.	2024-01-17

Every clearance here is in the API, with alerts when new ones post.